ARIA : Summary for ARIAD Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

ARIAD Pharmaceuticals, Inc. (ARIA)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
23.74+0.03 (+0.13%)
At close: 4:00PM EST
People also watch
ARNAARRYEXELACHNACAD
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close23.71
Open23.73
Bid23.70 x 500
Ask23.75 x 400
Day's Range23.70 - 23.75
52 Week Range4.37 - 23.81
Volume11,675,955
Avg. Volume10,290,541
Market Cap4.61B
Beta3.00
PE Ratio (TTM)-136.44
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC
    Investor's Business Daily4 days ago

    Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC

    Ariad had to put off requests from a potential suitor in order to lock in an increased buyout offer from Takeda Pharmaceuticals.

  • American City Business Journals4 days ago

    Ariad played hardball to boost Takeda buyout price, federal filings show

    Takeda’s $5.2 billion acquisition of Ariad Pharmaceuticals on Jan. 9 valued the Cambridge cancer drug firm at $24 per share, a 75 percent premium over its previous closing stock price. A federal filing by Ariad (ARIA) on Thursday includes a lengthy play-by-play of the negotiations, beginning with a phone call on Dec. 2 between Ariad CEO Paris Panayiotopoulos and Takeda CEO Christophe Weber. During the call, Panayiotopoulos told Weber that if Takeda was interested in making a “broader” deal, it should do so in writing, according to the filing.

  • Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017
    Investor's Business Daily4 days ago

    Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017

    Biotechs have a lot riding on drug data in 2017 with nearly two dozen firms reporting data in four key segments.